Clinical and genetic factors to inform reducing colorectal cancer disparitites in African Americans

Frontiers in Oncology

Volumn 8, Issue NOV, 2018, Pages

  Carethers, John M ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

African American; Cancer disparity; Colon; Colon cancer prevention; Colon cancer risk; Colorectal cancer

Indexed keywords

EPHRIN RECEPTOR A6; MUTL PROTEIN HOMOLOG 1;

AFRICAN AMERICAN; B LYMPHOCYTE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CAUCASIAN; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; COLONOSCOPY; COLORECTAL CANCER; DNA METHYLATION; ENVIRONMENTAL FACTOR; FRAMESHIFT MUTATION; GENE MUTATION; HEALTH DISPARITY; HEREDITY; HUMAN; IMMUNOSURVEILLANCE; INTESTINE FLORA; LIFESTYLE MODIFICATION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ONSET AGE; REVIEW; WESTERN DIET;

EID: 85063340845     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2018.00531     Document Type: Review

References (61)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. (2018) 68:7-30. 10.3322/caac.21442
2. Ashktorab H, Brim H, Kupfer SS, Carethers JM. Racial disparity in gastrointestinal cancer risk. Gastroenterology (2017) 153:910-23. 10.1053/j.gastro.2017.08.018
3. Ashktorab H, Vilmenay K, Brim H, Laiyemo AO, Kibreab A, Nouraie M. Colorectal cancer in young African Americans: is it time to revisit guidelines and prevention? Dig Dis Sci. (2016) 61:3026-30. 10.1007/s10620-016-4207-1
4. Carethers JM. The increasing incidence of colorectal cancers diagnosed in subjects under age 50 among races: cracking the conundrum. Dig Dis Sci. (2016) 61:2767-9. 10.1007/s10620-016-4268-1
5. DeSantis CE, Siegel RL, Sauer AG, Miller KD, Gedewa SA, Alcaraz KI, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. (2016) 66:290-308. 10.3322/caac.21340
6. Carethers JM. Screening for colorectal cancer in African Americans: determinants and rationale for an earlier age to commence screening. Dig Dis Sci. (2015) 60:711-21. 10.1007/s10620-014-3443-5
7. Ayanian JZ, Carethers JM. Bridging behavior and biology to reduce socioeconomic disparities in colorectal cancer risk. J Natl Cancer Inst. (2012) 104:1343-4. 10.1093/jnci/djs356
8. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology (1997) 112:594-642. 10.1053/gast.1997.v112.agast970594
9. Carethers JM. Racial and ethnic factors in the genetic pathogenesis of colorectal cancer. J Assoc Acad Minor Phys. (1999) 10:59-67.
10. Agrawal S, Bhupinderjit A, Bhutani MS, Boardman L, Nguyen C, Romero Y, et al. Colorectal cancer in African Americans. Am J Gastroenterol. (2005) 100:515-23. 10.1111/j.1572-0241.2005.41829.x
11. Carethers JM. Should African Americans be screened for colorectal cancer earlier? Nat Clin Pract Gastroenterol Hepatol. (2005) 2:352-3. 10.1038/ncpgasthep0241
12. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA., Inadomi JM, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009. Am J Gastroenterol. (2009) 104:739-50. 10.1038/ajg.2009.104
13. Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology (2017) 153:307-23. 10.1053/j.gastro.2017.05.013
14. Grady WM and Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology (2008) 135:1079-99. 10.1053/j.gastro.2008.07.076
15. Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology (2015) 149:1177-90. 10.1053/j.gastro.2015.06.047
16. Lieberman DA, Holub JL, Moravec MD, Eisen GM, Peters D, Morris CD. Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients. JAMA (2008) 300:1417-22. 10.1001/jama.300.12.1417
17. Lieberman DA, Williams JL, Holub JL, Morris CD, Logan JR, Eisen GM, et al. Race, ethnicity, and sex affect risk for polyps >9 mm in average-risk individuals. Gastroenterology (2014) 147:351-8. 10.1053/j.gastro.2014.04.037
18. Corley DA, Jensen CD, Marks AR, Zhao WK, de Boer J, Levin TR, et al. Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs. Clin Gastroenterol Hepatol. (2013) 11:172-80. 10.1016/j.cgh.2012.09.010
19. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. (2009) 150:1-8. 10.7326/0003-4819-150-1-200901060-00306
20. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population based, case-control study. Ann Intern Med. (2011) 154:22-30. 10.7326/0003-4819-154-1-201101040-00004
21. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, et al. Long-term colorectal cancer incidence and mortality after lower endoscopy. N Engl J Med. (2013) 369:1095-105. 10.1056/NEJMoa1301969
22. Schroy PC III, Coe A, Chen CA, O'Brien MJ, Heeren TC. Prevalence of advanced colorectal neoplasia in white and black patients undergoing screening colonoscopy in a safety-net hospital. Ann Intern Med. (2013) 159:13-20. 10.7326/0003-4819-159-1-201307020-00004
23. Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science (2018) 359:592-7. 10.1126/science.aah3648
24. Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA. (2014) 111:18321-6. 10.1073/pnas.1406199111
25. Yazici C, Wolf PG, Kim H, Cross TL, Vermillion K, Carroll T, et al. Race-dependent association of sulfidogenic bacteria with colorectal cancer. Gut (2017) 66:1983-94. 10.1136/gutjnl-2016-313321
26. Farhana L, Antaki F, Murshed F, Mahmud H, Judd SL, Nangia-Makker P, et al. Gut microbiome profiling and colorectal cancer in African Americans and Caucasian Americans. World J Gastrointest Pathophysiol. (2018) 9:47-58. 10.4291/wjgp.v9.i2.47
27. O'Keefe SJ, Li JV, Lahti L, Ou J, Carbonero F, Mohammed K, et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun. (2015) 6:6342. 10.1038/ncomms7342
28. Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J Gastroenterol. (2015) 21:9253-61. 10.3748/wjg.v21.i31.9253
29. Guindalini RS, Win AK, Gulden C, Lindor NM, Newcomb PA, Haile RW, et al. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology (2015) 149:1446-53. 10.1053/j.gastro.2015.07.052
30. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 487:330-7. 10.1038/nature11252
31. Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, et al. Novel recurrently mutated genes in African American colon cancers. Proc Natl Acad Sci USA. (2015) 112:1149-54. 10.1073/pnas.1417064112
32. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology (2008) 134:988-97. 10.1053/j.gastro.2008.01.015
33. Carethers JM. Hereditary, sporadic and metastatic colorectal cancers are commonly driven by specific spectrums of defective DNA mismatch repair components. Trans Am Clin Climatol Assoc. (2016) 127:81-97.
34. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. (2015) 372:2509-20. 10.1056/NEJMoa1500596
35. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (2017) 357:409-13. 10.1126/science.aan6733
36. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 117: 123-31. 10.1016/S0016-5085(99)70558-5
37. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. (2003) 349:247-57. 10.1056/NEJMoa022289
38. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, et al. Use of 5-fluorouracil and survival in patients with microsatellite unstable colorectal cancer. Gastroenterology (2004) 126: 394-401. 10.1053/j.gastro.2003.12.023
39. Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM. The mismatch repair complex hMutSα recognizes 5-fluoruracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology (2004) 127:1678-84. 10.1053/j.gastro.2004.10.001
40. Iwaizumi M, Tseng-Rogenski S, Carethers JM. DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. Cancer Biol Ther. (2011) 12:756-64. 10.4161/cbt.12.8.17169
41. Tajima A, Iwaizumi M, Tseng-Rogenski S, Cabrera BL, Carethers JM. Both hMutSα and hMut complexes participate in 5-fluoruracil cytotoxicity. PLoS ONE (2011) 6:e28117. 10.1371/journal.pone.0028117 oogle Scholar
42. Suzuki S, Iwaizumi M, Tseng-Rogenski S, Hamaya Y, Miyajima H, Kanaoka S, et al. Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status. Cancer Biol Ther. (2016) 17:760-80. 10.1080/15384047.2016.1178430
43. Suzuki S, Iwaizumi M, Yamada H, Hamaya Y, Furuta T, Kanaoka S, et al. MBD4 frameshift mutation caused by DNA mismatch repair deficiency enhances cytotoxicity by trifluridine, and active antitumor agent of TAS-102, in colorectal cancer cells. Oncotarget (2018) 9:11477-88. 10.18632/oncotarget.22484
44. Carethers JM, Murali B, Yang B, Doctolero RT, Tajima A, Basa R, et al. Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer. PLoS ONE (2014) 9:e100461. 10.1371/journal.pone.0100461
45. Ashktorab H, Ahuja S, Kannan L, Llor X, Ellis N, Xicola RM, et al. A meta-analysis of MSI frequency and race in colorectal cancer. Oncotarget (2016) 7:34546-57. 10.18632/oncotarget.8945
46. Tseng-Rogenski S, Chung H, Wilk MB, Zhang S, Iwaizumi M, Carethers JM. Oxidative stress induces nuclear-to-cytosol shift of hMSH3, a potential mechanism for EMAST in colorectal cancer cells. PLoS ONE (2012) 7:e50616. 10.1371/journal.pone.0050616
47. Tseng-Rogenski S, Hamaya Y, Choi D, Carethers JM. Interleukin 6 alters localization of hMSH3, leading to DNA mismatch repair defects in colorectal cancer cells. Gastroenterology (2015) 148:579-89. 10.1053/j.gastro.2014.11.027
48. Carethers JM. Microsatellite instability pathway and EMAST in colorectal cancer. Curr Colorectal Cancer Rep. (2017) 13:73-80. 10.1007/s11888-017-0352-y
49. Carethers JM, Koi M, Tseng-Rogenski S. EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression. Genes (2015) 6:185-205. 10.3390/genes6020185
50. Lee S-Y, Chung H, Devaraj B, Iwaizumi M, Han HS, Hwang D-Y, et al. Elevated microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasia. Gastroenterology (2010) 139:1519-25. 10.1053/j.gastro.2010.08.001
51. Lee S-Y, Miyai K, Han HS, Hwang D-Y, Seong MK, Chung H, et al. Microsatellite instability, EMAST, and morphology associations with T cell infiltration in colorectal neoplasia. Dig Dis Sci. (2012) 57:72-8. 10.1007/s10620-011-1825-5
52. Hamaya Y, Guarinos C, Tseng-Rogenski SS, Iwaizumi M, Das R, Jover R, et al. Efficacy of 5-fluorouracil adjuvant therapy for patients with EMAST-positive stage II/III colorectal cancers. PLoS ONE (2015) 10:e0127591. 10.1371/journal.pone.0127591
53. Devaraj B, Lee A, Cabrera BL, Miyai K, Luo L, Ramamoorthy S, et al. Relationship of EMAST and microsatellite instability among patients with rectal cancer. J Gastrointest Surg. (2010) 14:1521-8. 10.1007/s11605-010-1340-6
54. Koi M, Tseng-Rogenski SS, Carethers JM. Inflammation-associated microsatellite alterations: mechanisms and significance in the prognosis of patients with colorectal cancer. World J Gastrointest Oncol. (2018) 10:1-14. 10.4251/wjgo.v10.i1.1
55. Koi M, Carethers JM. The colorectal cancer immune microenvironment and approach to immunotherapies. Future Oncol. (2017) 13:1633-47. 10.2217/fon-2017-0145
56. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313:1960-4. 10.1126/science.1129139
57. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity (2016) 44:698-711. 10.1016/j.immuni.2016.02.025
58. Basa RCB, Davies V, Li X, Murali B, Shah J, Yang B, et al. Decreased anti-tumor cytotoxic immunity among colon cancers from African Americans. PLoS ONE (2016) 11:e0156660. 10.1371/journal.pone.0156660
59. Kupfer SS, Carr RM, Carethers JM. Reducing colorectal cancer risk among African Americans. Gastroenterology (2015) 149:1302-4. 10.1053/j.gastro.2015.08.033
60. Grubbs SS, Polite BN, Carney J Jr, Bowser W, Rogers J, Katurakes N, et al. Eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol. (2013) 31:1928-30. 10.1200/JCO.2012.47.8412
61. Polite BN, Adams-Campbell LL, Brawley OW, Bickell N, Carethers JM, Flowers CR, et al. Charting the future of cancer health disparities research: a position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. Cancer Res. (2017) 77:4548-55 10.1158/0008-5472.CAN-17-0623